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Abstract
Despite the availability of a preventive vaccine, chronic hepatitis B virus (HBV) infection-induced 
liver diseases continue to be a major global public health problem. HBV naturally infects only 
humans and chimpanzees. This narrow host range has hindered our ability to study the 
characteristics of the virus and how it interacts with its host. It is thus important to establish small 
animal models to study HBV infection, persistence, clearance and the immunopathogenesis of 
chronic hepatitis B. In this review, we briefly summarize currently available animal models for 
HBV research, then focus on mouse models, especially the recently developed humanized mice 
that can support HBV infection and immunopathogenesis in vivo. This article is part of a 
symposium in Antiviral Research on “From the discovery of the Australia antigen to the 
development of new curative therapies for hepatitis B: an unfinished story.”
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1. Introduction
Approximately 350 million people are chronically infected with hepatitis B virus (HBV), 
putting them at high risk of developing liver fibrosis/cirrhosis and eventually developing 
hepatocellular carcinoma (HCC) over several decades (Scaglione and Lok, 2012). The 
impaired immune response to viral antigens during chronic HBV infection is associated with 
persistent liver inflammation which leads to liver diseases (Guidotti and Chisari, 2006). The 
lack of robust animal models has hindered our understanding of how HBV interacts with 
host restriction factors to establish chronic infection (Bility et al., 2013). Moreover, our 
knowledge about how chronic infection leads to liver injury, cirrhosis and cancer, is also 
limited.
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HBV can only naturally infect humans and chimpanzees. To overcome this experimental 
limitation, several small animal models, such as HBV transgenic mice, the hydrodynamic-
based HBV DNA transfection model, the viral vector-based HBV genome transduction 
model and the human-mouse liver/immune system chimeric model of HBV replication and 
infection have been developed. These models should help us to understand the 
immunopathogenesis of chronic hepatitis B and should greatly facilitate the development of 
new treatments. In this review, we first briefly introduce the contribution of the chimpanzee 
and tree shrew models, then focus on progress made in the development of mouse models, 
especially the recently developed human-murine chimeric mouse models, for studying 
hepatitis B biology and therapy.
2. Contributions of the chimpanzee and tree shrew models to HBV research
The chimpanzee is susceptible to HBV infection, and has been employed to study 
pathogenesis, host immune responses and the evaluation of potential therapies since the 
1970s. Inoculation of chimpanzees with serum from human HBV carriers induced acute 
infection and hepatitis (Barker et al., 1973; Berquist et al., 1975). Chimpanzees played an 
essential role in evaluating the efficacy and safety of the yeast-produced recombinant 
HBsAg vaccine (McAleer et al., 1984).
The chimpanzee model has also contributed substantially to our understanding of HBV 
virus-host interactions. Genomic analysis of virus-induced and immune response-related 
genes in the liver of acutely infected chimpanzees indicated that HBV does not significantly 
induce an innate immune response during entry and expansion (Wieland et al., 2004). In 
contrast, a large number of T cell-derived IFN-γ-regulated genes are detected in the liver 
during viral clearance, reflecting the importance of an adaptive immune response in the 
control of HBV infection (Wieland et al., 2004). The immunological priming and outcome 
of infection was also dependent on the size of the HBV inoculum (Asabe et al., 2009). In 
vivo depletion experiments demonstrated that CD8 T cells, but not CD4 T cells were the 
main effector cells responsible for HBV clearance and pathogenesis during acute HBV 
infection in chimpanzees (Thimme et al., 2003). Viral clearance was shown to be mediated 
by both cytolytic and noncytolytic effector functions of the effector CD8 T cells (Guidotti 
and Chisari, 2001; Guidotti et al., 1999).
Chimpanzees can also be chronically infected with HBV, and chronic infections are 
associated with persistent inflammation in the liver, although the degree of the disease 
appears to be much milder than in humans (Shouval et al., 1980). This chronic infection 
model provides a platform for testing antiviral drugs. A recent example is the toll-like 
receptor 7 agonist (GS-9620), which activates signaling in immune cells of chronically 
HBV-infected chimpanzees to induce clearance of HBV-infected cells (Lanford et al., 
2013). Though the chimpanzee model provides a unique platform for HBV research, the use 
of this model for basic research and drug testing is restricted for ethical and also economic 
reasons. The necessity to use chimpanzees for preclinical research was recently reassessed in 
the USA, where the Institute of Medicine concluded that recent advances in cell-based 
models and in small animal models with human cells rendered the use of chimpanzees 
unnecessary (Wadman, 2011).
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In addition to higher primates, the tree shrew is the only other animal that can be 
experimentally infected with HBV (Walter et al., 1996; Yan et al., 1996). HBV infection in 
tree shrew results in viral replication in the liver, HBsAg secretion in the serum and 
subsequent appearance of anti-HBe and anti-HBs antibodies, recapitulating many aspects of 
self-limited acute hepatitis in humans (Walter et al., 1996). HBV infection can also result in 
chronic infection in tree shrew and can lead to development of hepatocellular carcinoma by 
week 160(Yan et al., 1996). Primary hepatocytes isolated from tree shrew are susceptible to 
HBV infection and serve as a valuable tool to study HBV infection in vitro (Glebe et al., 
2003; Glebe et al., 2005; Walter et al., 1996). Recently, a study using tree shrew hepatocytes 
found that sodium taurocholate cotransporting polypeptide (NTCP) is a functional receptor 
for human hepatitis B and D virus (Yan et al., 2012, 2015). However, experimental infection 
of tree shrews in vivo with HBV is not highly efficient, and there is currently a lack of both 
genetically uniform shrew strains as well as research tools for this model. These factors have 
hampered further adoption of this system for studying HBV infection.
Surrogate animal models for hepatitis B virus study, such as the woodchuck and duck 
models, have also contributed a lot to our understanding of hepadnavirus biology, and these 
models are still helpful for testing new drugs and treatments. We will not introduce these 
models in detail in the present article. Readers can refer to (Kosinska et al., 2015; Kulkarni 
et al., 2007) for reviews of WHV-infected woodchucks and (Cova and Zoulim, 2004) for 
DHBV-infected ducks.
3. HBV transgenic mouse models
Transgenic mice expressing either the complete HBV genome or individual genes provide 
valuable tools to study HBV replication, pathogenesis and therapies (Babinet et al., 1985; 
Chisari et al., 1986; Chisari et al., 1989; Chisari et al., 1985; Farza et al., 1988; Guidotti et 
al., 1995; Kim et al., 1991). When transgenically expressed in mice, small surface antigen 
(HBsAg) can be readily detected in the serum (Babinet et al., 1985; Chisari et al., 1985). 
These mice were tolerant to HBsAg and did not develop liver disease (Babinet et al., 1985; 
Chisari et al., 1985). However, transgenic mice that overexpressed HBsAg along with large 
surface antigen could retain the proteins in the ER, leading to its accumulation in the liver 
(Chisari et al., 1986), hepatocellular injury, chronic inflammation and eventually to 
hepatocellular carcinoma (HCC) (Chisari et al., 1987; Chisari et al., 1986; Chisari et al., 
1989).
Although mice that expressed high levels of the HBx antigen in the liver did not have 
obvious signs of liver injury and inflammation, they nevertheless developed HCC (Kim et 
al., 1991; Koike et al., 1994). These results indicate that HBx is oncogenic. Mice 
transgenically expressing the 1.3 copy over-length HBV genome (HBV1.3), which includes 
the viral promoters and regulatory elements, produce HBsAg, HBcAg and HBeAg (Guidotti 
et al., 1995). These mice produce levels of infectious virus in the blood that are comparable 
to those in chronically infected humans(Guidotti et al., 1995). High levels of HBV 
replication in the liver of mice does not induce hepatocellular injury, which further confirms 
that HBV is not cytopathic (Guidotti et al., 1995).
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Adoptive transfer of HBV-specific CTLs into HBV transgenic mice resulted in the clearance 
of HBsAg, accompanied by elevated serum alanine transaminase (ALT) (Ando et al., 1993; 
Moriyama et al., 1990). The CTLs induced an acute hepatitis and lysed HBsAg-expressing 
hepatocytes, and these effects were dependent on major histocompatibility class I (Ando et 
al., 1993; Moriyama et al., 1990). Besides killing the infected hepatocytes, the activated, 
adoptively transferred CTLs produced IFN-γ, which then stimulated the production of 
chemokines and recruited the infiltration of antigen-nonspecific lymphocytes and 
neutrophils. The infiltrated cells in the liver amplified the cytopathic effect of the CTLs 
(Ando et al., 1993). On the other hand, CTLs can also inhibit viral replication by 
noncytolytic mechanisms that involve secretion of IFN-γ and tumor necrosis factor-α (TNF-
α) (Guidotti et al., 1996). Thus, the immune system controls the virus through both cytolytic 
and noncytolytic mechanisms (Guidotti and Chisari, 2001).
The major clinical problem of HBV infection is HBV-induced chronic hepatitis. However, 
transgenic mice are immunologically tolerant to HBsAg and do not develop chronic liver 
disease. To model chronic hepatitis B, transgenic expression of the HBV genome was 
established in severe combined immunodeficient (SCID) mice. Adoptive transfer of 
unprimed, syngeneic splenocytes into HBV-transgenic SCID mice lead to partial clearance 
of the virus from both liver and serum and the development of chronic liver disease 
(Feitelson et al., 2004; Larkin et al., 1999). This model will permit identification of viral and 
host factors that contribute to chronic liver disease in the absence of tolerance.
HBV1.3 transgenic mice are not only suitable for the study of hepatitis B pathogenesis, but 
they also allow for the evaluation of therapeutic stratagems to inhibit viral replication. HBV 
replication in transgenic mice was shown to be inhibited by various cytokines such as IFN-γ, 
TNF-α, type I interferon and IL-18 (Kakimi et al., 2000; Kimura et al., 2002; McClary et al., 
2000). The efficacy of various nucleoside analogues, such as adefovir dipivoxil (Julander et 
al., 2002), lamivudine(Weber et al., 2002) and entecavir (Julander et al., 2003), were also 
tested in HBV-replicating transgenic mice.
In conclusion, the transgenic HBV mouse model contributes substantially to our 
understanding of hepatitis B immunopathogenesis in vivo and represents a suitable model to 
investigate novel therapeutic strategies for chronic infection. However, there are important 
limitations of this model. The study of viral entry and spread, as well as the development of 
drugs to inhibit these steps, are not possible using this model. Furthermore, these mice are 
not suitable for monitoring viral elimination, because the HBV genome is integrated in the 
mouse genome. All viral RNAs in this system are produced from the integrated viral 
genome and not from cccDNA, which is apparently absent in transgenic mouse hepatocytes. 
Finally, the tolerance induced by the transgenic viral proteins, probably starting from the 
embryonic stage, makes the study of therapeutic vaccines difficult. To study the mechanisms 
of HBV-induced liver disease and to develop therapeutic strategies for viral clearance, 
alternative mouse models were developed using hydrodynamic injection or viral vector-
mediated transduction of the HBV genome.
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4. Hydrodynamic-based transfection of HBV DNA in mice
Hydrodynamic injection is an efficient method to transfect genetic materials into the mouse 
liver in vivo (Liu et al., 1999). Transfection of hepatocytes in vivo by hydrodynamic 
injection with a replication-competent HBV genome is an alternative way to study viral 
replication and HBV-host interactions in mice, and this can circumvent the problem of 
central tolerance. After hydrodynamic injection of HBV DNA, HBV antigens and 
replicative intermediates are synthesized and virus can be detected in the blood (Yang et al., 
2002). The transfected immunocompetent mice displayed acute self-limiting hepatitis. The 
mice developed an HBV-specific antibody response and specific CTLs, which were 
associated with the disappearance of HBV serum antigens and HBV-positive hepatocytes. In 
contrast, expression of HBV antigens persisted in immunocompromised NOD-Scid mice 
(Yang et al., 2002), indicating that the host immune response may contribute to virus 
clearance.
The immune effectors which contribute to the clearance of HBV DNA were explored using 
a panel of immune-deficient mouse strains that were hydrodynamically transfected with the 
HBV genome (Yang et al., 2010). Results showed that CD4 and CD8 T cells, but not B 
cells, play a major role in HBV clearance. Interestingly, the innate immune effectors, such 
as type I interferon and TNF-α mediated pathways and NK cells, also contribute to the 
elimination of transfected HBV DNA (Yang et al., 2010). However, it should be noted that 
the persistence of HBV transgenes in mouse liver by hydrodynamic transfection is 
dependent on the mouse genetic background and the plasmid backbone (Huang et al., 2006). 
HBV surface antigenemia persisted for >6 months in around 40% of C57BL/6 mice after 
hydrodynamic injection of pAAV/HBV1.2 plasmids but not the pGEM4Z/HBV1.2 plasmids 
(Huang et al., 2006). It is likely that specific sequences in the AAV backbone could regulate 
the expression of the transgenes and lead to persistent expression of HBV surface antigen. 
Unlike in C57BL/C mice, serum HBsAg level dropped quickly 1 week after hydrodynamic 
injection of pAAV-HBV1.2 into Balb/C mice (Huang et al., 2006). This result indicates that 
genetic backgrounds indeed influence HBV clearance in mice. Thus, for the study of HBV 
tolerance, C57BL/6 mice hydrodynamically injected with pAAV/HBV1.2 plasmids can 
serve as a useful model to investigate mechanisms and therapies.
Experiments using the pAAV-HBV1.2 hydrodynamic injection model have shown that the 
HBV nucleocapsid determines HBV persistence in both C57BL/6 and Balb/C mice (Lin et 
al., 2010). The capsid structure of HBV, but not the free core protein, seems important for 
the induction HBV-specific antibody and CTL responses. In addition to the viral factors, 
host factors also affect virus persistence. HBV clearance in humans is heavily dependent on 
the age at the time of exposure. A recent report suggests that the gut microbiota contribute to 
the age-dependence of HBV clearance, using a hydrodynamic transfection mouse model 
(Chou et al., 2015).
The pAAV-HBV1.2 hydrodynamic injection model also provides a platform for testing 
therapies for HBV infection. Liver-infiltrating T cells from mice with HBV persistence 
expressed higher level of programmed death 1(PD-1), and blockade of the PD-1 pathway 
not only reversed T cell dysfunction but also reduced HBV persistence (Tzeng et al., 2012). 
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Another report showed that IL-15 treatment can suppress HBV replication in pAAV-
HBV1.2 transfected mice (Yin et al., 2012). The HBV regulatory protein X (HBx) has been 
shown to enhance viral replication in vivo (Keasler et al., 2007). Treatment with 
bifunctional 5’-triphosphate short interfering RNAs targeting X (3p-HBx-siRNAs) not only 
directly reduced HBx and HBV replication, but also triggered type I IFN signaling through 
the RIG-I pathway to inhibit HBV in HBV carrier mice (Han et al., 2011).
5. Transduction of HBV DNA in mice
Another route to deliver HBV genomes into the liver of mice is by adenoviral vector or 
adeno-associated virus vector. Adenoviral vectors are efficient for transduction of liver cells 
of immunocompetent mice(Bramson et al., 1995), and HBV-specific T cell and antibody 
responses can be detected after high dose infection (109 infectious units per mouse) of Ad-
HBV transduction (von Freyend et al., 2011). However, transduction of large amounts of 
HBV genome using high doses of adenovirus results in only transient HBV replication in the 
liver (Huang et al., 2012) because adenoviral infection induces a strong immune response in 
mice, resulting in HBV clearance (Hartman et al., 2007). Only infection of mice with low 
doses of adenoviral vector (108 infectious units per mouse) results in persistent HBV 
infection. Mice transduced with a low dose neither develop a strong HBV-specific T-cell 
response nor produce antibodies against HBV. This model could be used to study the 
pathogenesis of chronic HBV infection and develop new therapeutic strategies. However, it 
should be noted that high levels of HBV, which are commonly detected in chronic hepatitis 
B patients, could not be recapitulated in this model.
Compared to adenovirus transduction, adeno-associated virus (AAV) infection does not 
induce an obvious immune response (Mingozzi et al., 2003). In addition, in vivo hepatic 
gene transfer through AAV vectors can induce immune tolerance to the transgene (Mingozzi 
et al., 2003). Thus, AAV vectors should be an ideal vehicle to deliver HBV DNA into the 
liver. Recently, several groups successfully used AAV vectors to transfer replication-
competent HBV genomes (Dion et al., 2013; Dong et al., 2010; Wang et al., 2012; Yang et 
al., 2014). Yang et al. reported that AAV/HBV induces sustained viremia in both neonatal 
and adult mice. Similar to chronically infected patients, mice infected with AAV/HBV were 
negative for antibodies against HBsAg, and the AAV8/HBV-infected mice failed to elicit an 
HBV-specific immune response upon immunization with conventional HBV vaccine. In the 
other report, HLA-A2/DR1 mice transduced with 5 × 1010 viral genome equivalents of an 
AAV serotype 2/8 chimera lead to persistence of HBV DNA, HBsAg and HBeAg in serum 
for at least 1 year (Dion et al., 2013). While HBV replication intermediates and transcripts 
were detected in the livers of the AAV2/8/HBV infected mice, no significant inflammation 
was observed in the liver, and T cells were tolerant to HBV antigens (Dion et al., 2013).
In order to identify a vaccine that can potentially circumvent the immune tolerance induced 
by AAV/HBV infection, Yang et al. used TLR9 agonist CpG-B as an adjuvant, and found 
that AAV/HBV-infected mice vaccinated with HBsAg/CpG induced strong HBV-specific 
antibody production and T-cell responses, leading to clearance of viremia (Yang et al., 
2014). Furthermore, both HBV DNA and protein were significantly reduced in the livers of 
AAV/HBV-infected mice (Yang et al., 2014). Martin et al. reported that vaccination of 
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AAV/HBV infected mice with TG1050, a non-replicative adenovirus serotype 5 encoding a 
large HBV fusion protein composed of two HBV envelope domains, a truncated HBV core 
and a modified HBV polymerase, induced both splenic and intrahepatic functional T cells 
specific to HBV and a significant reduction of circulating viral markers (Martin et al., 2014).
In conclusion, HBV genome transfer by hydrodynamic injection or by AAV vector 
transduction results in sustained viremia and immune tolerance, which resemble clinical 
HBV carriers. This nontransgenic mouse model is therefore particularly suited to develop 
therapeutic interventions to clear HBV from transfected or transduced cells. The major 
limitations of this model are that there is no natural infection and, most importantly, there is 
no re-infection of mouse hepatocytes. Since HBV clearance in humans entails not only the 
elimination of virus from infected hepatocytes, but also control of HBV spread by new 
infection, a model permissive for true HBV infection is an important research need.
6. Human-murine liver chimeric mouse models
Currently, three kinds of human liver chimeric models are available to study HBV infection 
and test therapeutics. The first is based on transgenic mice with the urokinase plasminogen 
activator (uPA) gene (Rhim et al., 1994), expressed specifically in the liver under the control 
of the mouse albumin promoter. However, over-expression of the uPA gene in an 
uncontrolled manner leads to high lethality of newborn pups, so that newborn uPA mice 
must be rapidly transplanted with healthy hepatocytes. Handling of uPA mice therefore 
became expensive and time-consuming (Vanwolleghem et al., 2010).
A big improvement was made by using a non-liver specific major urinary protein (MUP) 
promoter to generate MUP-uPA SCID/Beige mice, which are generally healthier than Alb-
uPA mice and therefore provide a longer window for engraftment with human 
hepatocytes(Tesfaye et al., 2013). The second mouse model is based on the fumaryl 
acetoacetate hydrolase (Fah) knockout mice, including the FRG (Azuma et al., 2007), NOD-
FRG (Vaughan et al., 2012) and NRG-FAH (Li et al., 2014). Knockout of Fah results in the 
hepatic accumulation of toxic tyrosine metabolitic intermediates and the death of mouse 
hepatocytes. The advantage of Fah knockout mice, compared to uPA mice, is that the mice 
are much healthier and easier to handle, and liver injury can be controlled by administration 
and withdrawal of 2-(2-nitro-4-fluoromethylbenzoyl)-1,3-cyclohexanedione (NTBC), which 
blocks the accumulation of toxic intermediates caused by Fah knockout(Azuma et al., 2007; 
Bissig et al., 2010). Maintenance of the Fah knockout colony only requires supplementation 
of the water with NTBC.
The third mouse model is based on the recently-generated TK-NOG mice (Hasegawa et al., 
2011), which carry the herpes simplex virus (HSV) thymidine kinase (TK) transgene under 
the control of hepatic specific Alb promoter. Similar to Fah knockout mice, the TK-NOG 
mouse liver damage occurs in a controlled manner. Specific mouse hepatocyte depletion can 
be achieved by administration of a pro-drug, gancyclovir (GCV). One disadvantage of TK-
NOG mice is that male mice are sterile, and each batch of mice should be genotyped for TK 
positivity.
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The above three mouse models all have high levels of human hepatocyte repopulation, as 
evidenced by the high human serum albumin level (Bissig et al., 2010; Dandri et al., 2001; 
Hasegawa et al., 2011; Kosaka et al., 2013; Vanwolleghem et al., 2010). The surgical 
procedure to generate human hepatocyte chimeric mice is rather simple, and involves 
intrasplenic injection of between one and several million primary hepatocytes. Usually, it 
will take 2–3 months to reach workable reconstitution of human hepatocytes, which can 
vary from a few percent to over 95 percent of hepatocytes within the mouse liver (Bissig et 
al., 2010; Hasegawa et al., 2011; Kosaka et al., 2013).
Human chimeric liver mice have been used to evaluate HBV antivirals in vivo, including 
polymerase inhibitors such as lamivudine, entecavir and adefovir (Bissig et al., 2010; Dandri 
et al., 2005; Tsuge et al., 2005) and entry inhibitors such as Myrcludex-B, which is derived 
from the HBV large S protein (Oehler et al., 2014; Petersen et al., 2008). This model is also 
used to study HBV covalently closed circular DNA (cccDNA) biology in vivo 
(Lutgehetmann et al., 2010). It was shown that, in the absence of antiviral drugs, cell 
division in the setting of liver regeneration induced strong destabilization of the cccDNA 
reservoir, leading to cccDNA clearance in the great majority of chronically infected 
hepatocytes.
Because the chimeric mice are genetically immune deficient, the immune-mediated 
inhibition and/or clearance of HBV-infected hepatocytes cannot be evaluated in these 
models. However, in the absence of an adaptive immune system, these models can allow for 
the investigation of the antiviral effect of some innate immunomodulators, such as IFN-α 
(Belloni et al., 2012; Lutgehetmann et al., 2011; Tsuge et al., 2011). IFN-α treatment was 
shown to inhibit HBV transcription in this system by promoting epigenetic repression of the 
cccDNA template(Belloni et al., 2012). HBV, in turn, was found to counteract the inhibition 
by down-regulating the IFN-stimulated genes or blocking the IFN signaling pathway, by 
inhibiting STAT1 translocation into the nucleus (Lutgehetmann et al., 2011; Tsuge et al., 
2011). Thus, human chimeric mice are useful for the study the HBV and host cell 
interactions, but only in the context of innate immunity.
It is still technically challenging to study HBV infection using cell culture models, because 
these do not support secondary rounds of infection. Human liver chimeric mice, on the other 
hand, are permissible for spreading infection, allowing for more relevant investigation of the 
biology of chronic hepatitis B. Experimentation with HBV bearing different mutations, or 
from different genotypes (Sugiyama et al., 2006; Tanaka et al., 2008; Tsuge et al., 2010; 
Tsuge et al., 2005), has furthered our understanding of HBV genes. For example, HBeAg 
was demonstrated to be unnecessary for viral infection and replication (Tsuge et al., 2005). 
However, HBx is indispensable for viral replication in vivo (Tsuge et al., 2010).
Ectopic transplantation of human liver tissue under the kidney capsule can also support 
HBV replication (Bocher et al., 2000; Eren et al., 2000; Ilan et al., 1999; Ohashi et al., 
2000). These models were used to assess some antivirals in the early years. However, 
because the human liver engraftment in this model does grow and is relatively small in 
volume compared to the chimeric livers in the above models, the HBV titer in the blood was 
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lower and viremia duration was short. This model is now seldom used, as human liver 
chimeric mice are widely available.
It is well known that HBV is non-cytopathic, and HBV infection induced-liver diseases are 
mediated by host immune responses. While the human-mouse liver chimeric model contains 
humanized liver, it does not have a human immune system. Therefore this model is not 
suitable to study how human immune cells interact with HBV and cause liver disease. 
Chimeric mice with both human liver and immune system are necessary to study the 
immune-pathogenesis of HBV and to develop immuno-therapeutic treatments.
7. Humanized mouse models with both human liver and immune cells
To elucidate the mechanism of HBV-induced liver diseases and enable immunotherapeutic 
testing, we recently developed the novel NSG/Jo2 model, which is an immunodeficient 
mouse model that enables human liver cells and functional immune system development 
following transplantation with human fetal liver-derived hematopoietic stem cells and liver 
progenitor cells (Bility et al., 2014a).The NSG/Jo2 model is derived from the NOD-scid−/−-
gamma chain−/− (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ) mouse with the human HLA-A2 
transgene, and it utilizes the Jo2 antibody (mouse CD95 activating antibody) as a means of 
selectively inducing apoptosis in mouse hepatocytes (Bility et al., 2014a). Intrahepatic 
transplantation of immunodeficient mice with human CD34+ hematopoietic stem cells and 
human hepatic progenitor cells purified from 15–18 weeks old human fetal liver tissue into 
newborn immuno-deficient mice results in hematopoietic cell development. Conditional 
induction of mouse hepatocyte apoptosis then results in human hepatocyte regeneration 
(Bility et al., 2014a; Washburn et al., 2011). A human immune system is developed at 12 
weeks post-transplantation, along with human hepatocyte regeneration, as measured by 
human CD45+ cells and sub-lineages and human albumin levels in the blood, respectively 
(Bility et al., 2014a; Washburn et al., 2011).
Most importantly, the double-humanized immune system and liver-reconstituted mice 
exhibit normal liver physiology and structure, with no sign of liver disease (Bility et al., 
2014a; Washburn et al., 2011). The A2/NSG-hu HSC/Hep humanized mouse model 
supported persistent HBV infection, human immune responses, chronic liver inflammation 
and fibrosis. HBV-mediated liver immune impairment and liver disease were associated 
with high level of infiltrated human immunosuppressive/pro-fibrogenic macrophages. The 
results of this study suggest a critical role for macrophage activation in hepatitis B-induced 
liver diseases, thus providing a novel therapeutic target. This novel humanized mouse model 
provides a valuable platform for studying HBV infection, human immune response and liver 
diseases. (Bility et al., 2014a).
In addition, we reported another novel humanized mouse model, namely the AFC8 model, 
which is derived from the Balb/C-RAG2-γC-null immuno-deficient mouse (double-
knockout [DKO]) carrying a liver-specific transgene with inducible apoptotic activity, that 
enables human liver cells and immune system development and supports HCV infection 
following transplantation with human fetal liver-derived hematopoietic stem cells and liver 
progenitor cells (Bility et al., 2014b; Bility et al., 2012; Washburn et al., 2011).
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Although the recently reported humanized mouse models with human liver cells and 
immune system have enabled the study of the immunopathogenic mechanisms of chronic 
HBV-induced liver disease, these models have several limitations. The human immune 
system in the DKO mouse background is not fully developed, with deficiencies in antigen-
specific T- and B-cell responses (Aryee et al., 2014; Shultz et al., 2011; Washburn et al., 
2011). The NSG mice have improved antigen-specific T and B cell responses, compared to 
the DKO mice, but they still do not generate a completely functional human immune system 
(Aryee et al., 2014; Bility et al., 2014a; Shultz et al., 2011). Additionally, the human liver 
cell repopulation in the hepatic progenitor cell-reconstituted animals is relatively reduced, 
compared to adult hepatocyte-reconstituted mice (Bissig et al., 2010; Washburn et al., 2011).
Furthermore, the differentiation state of hepatic progenitor cells is also relatively immature 
(Washburn et al., 2011). HBV/HCV infection of humanized mice with human liver and 
immune system results in relatively lower viral replication, when compared to adult 
hepatocyte-transplanted mice (Bility et al., 2014a; Bissig et al., 2010; Washburn et al., 
2011), which is most likely due to the low hepatocyte repopulation level and the immature 
state of the hepatocytes. However, the human immune system could also be playing a role in 
controlling viral replication, albeit inefficiently (Bility et al., 2014a; Washburn et al., 2011). 
The development of humanized mouse models with high reconstitution of fully-
differentiated human hepatocytes, along with a completely competent human immune 
system, remains the goal for developing small animal models for studying chronic hepatitis 
B and associated inflammatory liver diseases (Bility et al., 2013; de Jong et al., 2010; 
Legrand et al., 2009; Strick-Marchand et al., 2015).
8. Summary and Perspectives
HBV naturally only infects human and chimpanzees; this narrow host range has hindered 
our understanding of HBV biology. Thus, a well-defined small animal model which 
supports robust infection is essential for us to understand the infection, replication and 
pathogenesis of chronic hepatitis B and to develop therapeutics.
Several mouse models have been developed for HBV study, each with its own advantages 
and disadvantages (summarized in Table 1). Transgenic mice expressing either the complete 
HBV genome or single viral genes have allowed investigators to study the replication, gene 
expression, and immunopathogenesis of HBV infection. However, the immune system of 
transgenic mice is tolerant to the virus, and the mice don’t show signs of hepatitis. Chronic 
hepatitis can be achieved by the adoptive transfer of anti-HBV CTLs into immunocompetent 
HBV transgenic mice, or by the transfer of syngeneic spleen cells into HBV transgenic 
SCID mice. From these models, we now know that the host immune response serves as a 
double-edged sword toward HBV infection, inhibiting replication while also contributing to 
the development of chronic liver disease.
Although HBV-transgenic mice have been used to test numerous drugs, the model cannot be 
used for the study of HBV entry spread, or to test drugs that inhibit these steps. Furthermore, 
these mice are not suitable for monitoring viral elimination, because the HBV genome is 
integrated into the host chromosome.. The immune system also exhibits central tolerance to 
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the transgenic gene products, making the study of therapeutic vaccines in this model 
difficult. Alternative models were developed by transfecting HBV DNA into the liver cells 
by hydrodynamic-based gene delivery methods or by transduction using AAV vectors. 
However, none of these models allow us to investigate real HBV infection and its interaction 
with a natural host immune system.
Recent progress in human-mouse liver chimeric models allows us to study HBV virus 
infection of human hepatocytes and to test therapeutics. Even more importantly, the 
chimeric mouse model with both human liver and immune system provides a unique 
platform to study how the virus interacts with the human immune system in vivo and to 
manipulate the human immune system to treat HBV infection.
Many preclinical studies based on immunotherapy are now ongoing to cure chronic hepatitis 
B. However, most such studies are performed in HBV-transgenic or transfected/transduced 
mice. Differences between the mouse and human immune system will probably make 
translation difficult. The humanized mouse with both human liver and human immune 
system should serve as a unique model for the development of immunotherapeutic strategies 
for HBV infection. Efforts are needed to improve the reconstitution of both the human liver 
and human immune system in the same mouse, to make this model more efficient and more 
applicable for immuno-intervention.
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• It is important to establish small animal models to study HBV infection, 
persistence and immunopathogenesis.
• We first review the contribution of chimpanzee and tree shrew models of 
chronic hepatitis B.
• We then review transgenic mouse models, hydrodynamic-based transfection of 
HBV DNA and transduction of HBV DNA.
• We then review human-murine liver chimeric mouse models and humanized 
mice with both human liver and immune cells.
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